Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1981 2
1982 4
1983 31
1984 9
1985 3
1986 4
1987 3
1988 7
1989 2
1990 3
1991 3
1992 3
1993 1
1994 5
1995 6
1996 4
1997 5
1998 8
1999 11
2000 10
2001 35
2002 29
2003 33
2004 46
2005 52
2006 52
2007 45
2008 47
2009 45
2010 42
2011 58
2012 62
2013 56
2014 39
2015 30
2016 30
2017 31
2018 15
2019 20
2020 22
2021 23
2022 19
2023 19
2024 15
2025 15
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

880 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI).
Iosifescu DV, Jones A, O'Gorman C, Streicher C, Feliz S, Fava M, Tabuteau H. Iosifescu DV, et al. J Clin Psychiatry. 2022 May 30;83(4):21m14345. doi: 10.4088/JCP.21m14345. J Clin Psychiatry. 2022. PMID: 35649167 Free article. Clinical Trial.
Results: A total of 327 patients were randomized: 163 patients to dextromethorphan-bupropion and 164 patients to placebo. Mean baseline MADRS total scores were 33.6 and 33.2 in the dextromethorphan-bupropion and placebo groups, respectively. ...The most common adver …
Results: A total of 327 patients were randomized: 163 patients to dextromethorphan-bupropion and 164 patients to placebo. Mean baseli …
Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial.
Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T, Lawrence D, Ascher J, Russ C, Krishen A, Evins AE. Anthenelli RM, et al. Lancet. 2016 Jun 18;387(10037):2507-20. doi: 10.1016/S0140-6736(16)30272-0. Epub 2016 Apr 22. Lancet. 2016. PMID: 27116918 Free article. Clinical Trial.
Varenicline-treated participants achieved higher abstinence rates than those on placebo (odds ratio [OR] 3.61, 95% CI 3.07 to 4.24), nicotine patch (1.68, 1.46 to 1.93), and bupropion (1.75, 1.52 to 2.01). Those on bupropion and nicotine patch achieved higher abstin …
Varenicline-treated participants achieved higher abstinence rates than those on placebo (odds ratio [OR] 3.61, 95% CI 3.07 to 4.24), nicotin …
Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial.
Grilo CM, Lydecker JA, Fineberg SK, Moreno JO, Ivezaj V, Gueorguieva R. Grilo CM, et al. Am J Psychiatry. 2022 Dec 1;179(12):927-937. doi: 10.1176/appi.ajp.20220267. Epub 2022 Oct 26. Am J Psychiatry. 2022. PMID: 36285406 Free PMC article. Clinical Trial.
RESULTS: Intention-to-treat binge-eating remission rates were 17.7% in the placebo group, 31.3% in the naltrexone-bupropion group, 37.1% in the BWL+placebo group, and 57.1% in the BWL+naltrexone-bupropion group. ...The rates of participants attaining 5% weight loss …
RESULTS: Intention-to-treat binge-eating remission rates were 17.7% in the placebo group, 31.3% in the naltrexone-bupropion group, 37 …
Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, Kim DD, Dunayevich E; COR-I Study Group. Greenway FL, et al. Lancet. 2010 Aug 21;376(9741):595-605. doi: 10.1016/S0140-6736(10)60888-4. Epub 2010 Jul 29. Lancet. 2010. PMID: 20673995 Clinical Trial.
Mean change in bodyweight was -1.3% (SE 0.3) in the placebo group, -6.1% (0.3) in the naltrexone 32 mg plus bupropion group (p<0.0001 vs placebo) and -5.0% (0.3) in the naltrexone 16 mg plus bupropion group (p<0.0001 vs placebo). 84 (16%) participants assigned …
Mean change in bodyweight was -1.3% (SE 0.3) in the placebo group, -6.1% (0.3) in the naltrexone 32 mg plus bupropion group (p<0.0 …
Antidepressant Augmentation versus Switch in Treatment-Resistant Geriatric Depression.
Lenze EJ, Mulsant BH, Roose SP, Lavretsky H, Reynolds CF 3rd, Blumberger DM, Brown PJ, Cristancho P, Flint AJ, Gebara MA, Gettinger TR, Lenard E, Miller JP, Nicol GE, Oughli HA, Pham VT, Rollman BL, Yang L, Karp JF. Lenze EJ, et al. N Engl J Med. 2023 Mar 23;388(12):1067-1079. doi: 10.1056/NEJMoa2204462. Epub 2023 Mar 3. N Engl J Med. 2023. PMID: 36867173 Free PMC article. Clinical Trial.
The difference between the aripiprazole-augmentation group and the switch-to-bupropion group was 2.79 points (95% CI, 0.56 to 5.02; P = 0.014, with a prespecified threshold P value of 0.017); the between-group differences were not significant for aripiprazole augmentation …
The difference between the aripiprazole-augmentation group and the switch-to-bupropion group was 2.79 points (95% CI, 0.56 to 5.02; P …
Bupropion and Naltrexone in Methamphetamine Use Disorder.
Trivedi MH, Walker R, Ling W, Dela Cruz A, Sharma G, Carmody T, Ghitza UE, Wahle A, Kim M, Shores-Wilson K, Sparenborg S, Coffin P, Schmitz J, Wiest K, Bart G, Sonne SC, Wakhlu S, Rush AJ, Nunes EV, Shoptaw S. Trivedi MH, et al. N Engl J Med. 2021 Jan 14;384(2):140-153. doi: 10.1056/NEJMoa2020214. N Engl J Med. 2021. PMID: 33497547 Free PMC article. Clinical Trial.
In the first stage, 18 of 109 participants (16.5%) in the naltrexone-bupropion group and 10 of 294 (3.4%) in the placebo group had a response. In the second stage, 13 of 114 (11.4%) in the naltrexone-bupropion group and 2 of 111 (1.8%) in the placebo group had a res …
In the first stage, 18 of 109 participants (16.5%) in the naltrexone-bupropion group and 10 of 294 (3.4%) in the placebo group had a …
Naltrexone/bupropion for binge-eating disorder: A randomized, double-blind, placebo-controlled trial.
Grilo CM, Lydecker JA, Jastreboff AM, Pittman B, McKee SA. Grilo CM, et al. Obesity (Silver Spring). 2023 Nov;31(11):2762-2773. doi: 10.1002/oby.23898. Epub 2023 Sep 26. Obesity (Silver Spring). 2023. PMID: 37751990 Free PMC article. Clinical Trial.
This study tested the efficacy of naltrexone/bupropion for BED. METHODS: A randomized, double-blind, placebo-controlled, 12-week trial tested naltrexone/bupropion for BED with and without obesity. ...RESULTS: Mixed models of binge-eating frequency revealed significa …
This study tested the efficacy of naltrexone/bupropion for BED. METHODS: A randomized, double-blind, placebo-controlled, 12-week tria …
Effect of AXS-05 (Dextromethorphan-Bupropion) in Major Depressive Disorder: A Randomized Double-Blind Controlled Trial.
Tabuteau H, Jones A, Anderson A, Jacobson M, Iosifescu DV. Tabuteau H, et al. Am J Psychiatry. 2022 Jul;179(7):490-499. doi: 10.1176/appi.ajp.21080800. Epub 2022 May 18. Am J Psychiatry. 2022. PMID: 35582785 Clinical Trial.
Most secondary outcomes favored dextromethorphan-bupropion. The most common adverse events with dextromethorphan-bupropion were dizziness, nausea, dry mouth, decreased appetite, and anxiety. ...CONCLUSIONS: In patients with major depression, dextromethorphan-bupr …
Most secondary outcomes favored dextromethorphan-bupropion. The most common adverse events with dextromethorphan-bupropion wer …
Bupropion hydrochloride.
Dufresne RL, Weber SS, Becker RE. Dufresne RL, et al. Drug Intell Clin Pharm. 1984 Dec;18(12):957-64. doi: 10.1177/106002808401801201. Drug Intell Clin Pharm. 1984. PMID: 6439541 Review.
Bupropion is a trimethylated monocyclic phenylaminoketone that is an effective antidepressant in humans. ...Bupropion appears to be safe and effective in both adult and geriatric depressed patients. ...
Bupropion is a trimethylated monocyclic phenylaminoketone that is an effective antidepressant in humans. ...Bupropion appears …
A randomized clinical trial on the effects of bupropion and buprenorphine on the reduction of methamphetamine craving.
Ahmadi J, Sahraian A, Biuseh M. Ahmadi J, et al. Trials. 2019 Jul 30;20(1):468. doi: 10.1186/s13063-019-3554-6. Trials. 2019. PMID: 31362784 Free PMC article. Clinical Trial.
BACKGROUND: The purpose of this study was to compare the effect of 300 mg of bupropion and 8 mg of buprenorphine per day on the treatment of methamphetamine withdrawal cravings over a 2-week treatment interval. ...We should note that it is to be expected that craving decre …
BACKGROUND: The purpose of this study was to compare the effect of 300 mg of bupropion and 8 mg of buprenorphine per day on the treat …
880 results